ClinicalTrials.gg
CompletedNCT02675426SELECT-NEXTUpdated Apr 11, 2023Results posted

A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone

A Phase 3 interventional study of Placebo and Upadacitinib in Rheumatoid Arthritis, sponsored by AbbVie. Completed at 167 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-11.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
661
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.

Enrollment
3rd of 19
661 · median 300
Started
2015
the only one that year
Phase 3
7 of 19
none open now
Registered
5th of 19
by date
Lead sponsor
13 of 19
AbbVie

Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 7 in phase 3, and was the 5th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing upadacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objectives of this study are to compare the efficacy, safety, and tolerability of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of adults with moderately to severely active rheumatoid arthritis who were on a stable dose of csDMARDs and had an inadequate response to csDMARDs.

Read the detailed description

This Phase 3 multicenter study includes two periods. Period 1 is a 12-week, randomized, double-blind, parallel-group, placebo-controlled period designed to compare the safety and efficacy of upadacitinib 30 mg once daily and upadacitinib 15 mg once daily versus placebo for the treatment of signs and symptoms of adults with moderately to severely active rheumatoid arthritis (RA) who were on a stable dose of csDMARDs and had an inadequate response to csDMARDs.

Period 2 is a 248-week blinded long-term extension period to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 30 mg once daily and upadacitinib 15 mg once daily in participants who completed Period 1.

Participants were to be randomized in a 2:2:1:1 ratio using interactive response technology (IRT) to receive double-blind study drug in one of the following treatment groups:

  • Group 1: Upadacitinib 30 mg QD in Period 1 → Upadacitinib 30 mg QD in Period 2
  • Group 2: Upadacitinib 15 mg QD in Period 1 → Upadacitinib 15 mg QD in Period 2
  • Group 3: Placebo in Period 1 → Upadacitinib 30 mg QD in Period 2
  • Group 4: Placebo in Period 1 → Upadacitinib 15 mg QD in Period 2

Randomization was stratified by prior exposure to biological disease-modifying anti-rheumatic drug (bDMARD) (yes/no) and geographic region.

Following Protocol Amendment 6.0 approval in December 2019, all participants still on study received open-label upadacitinib 15 mg QD, including those on upadacitinib 30 mg QD, with the earliest switch occurring at the Week 168 visit.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Musculoskeletal Disease
  • Arthritis
  • Joint Disease
  • Anti-inflammatory agents
  • Antirheumatic agents
  • Upadacitinib
  • ABT-494
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or female, at least 18 years old.
  • Diagnosis of rheumatoid arthritis (RA) for greater than or equal to 3 months.
  • Subjects have been receiving conventional synthetic DMARD (csDMARD) therapy for greater than or equal to 3 months and on a stable dose for greater than or equal to 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide.
  • Meets the following minimum disease activity criteria: greater than or equal to 6 swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
  • Subjects with prior exposure to at most one biologic DMARD (bDMARD) may be enrolled (up to 20% of study population) if they have documented evidence of intolerance to bDMARDs or limited exposure (less than 3 months) and have satisfied required .

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
  • History of inflammatory joint disease other than RA. History of secondary Sjogren's Syndrome is permitted.
  • Subjects who are considered inadequate responders to bDMARD therapy as determined by the Investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
661 participants (actual)

Study arms

  • Experimental
    Upadacitinib 15 mg

    Period 1: Participants receive upadacitinib 15 mg once daily for 12 weeks. Period 2: Participants continue to receive upadacitinib 15 mg once daily for an additional 248 weeks.

    Drug: Upadacitinib

  • Experimental
    Upadacitinib 30 mg

    Period 1: Participants receive upadacitinib 30 mg once daily for 12 weeks. Period 2: Participants continue to receive upadacitinib 30 mg once daily for an additional 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily.

    Drug: Upadacitinib

  • Experimental
    Placebo / Upadacitinib 15 mg

    Period 1: Participants receive placebo once daily for 12 weeks. Period 2: Participants receive upadacitinib 15 mg once daily for 248 weeks.

    Drug: Placebo · Drug: Upadacitinib

  • Experimental
    Placebo / Upadacitinib 30 mg

    Period 1: Participants receive placebo once daily for 12 weeks. Period 2: Participants receive upadacitinib 30 mg once daily for 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily.

    Drug: Placebo · Drug: Upadacitinib

Interventions

  • DrugPlacebo

    Tablet; Oral

  • Tablet; Oral

    Also known as: ABT-494, Rinvoq

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

    The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  2. Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12

    The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12

    The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.

    Time frame: Baseline and Week 12

  2. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

    Time frame: Baseline and Week 12

  3. Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary (PCS) Score at Week 12

    The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 12

  4. Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12

    Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6. DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.

    Time frame: Week 12

  5. Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12

    Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10. CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.

    Time frame: Week 12

  6. Change From Baseline in Duration of Morning Stiffness at Week 12

    Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days.

    Time frame: Baseline and Week 12

  7. Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12

    The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a five point Likert scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from Baseline indicates improvement.

    Time frame: Baseline and week 12

  8. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  9. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  10. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 1

07

Results

Posted Oct 7, 2019

Participant flow

Participants were randomized at 149 centers in 35 countries in North America, eastern and western Europe, Asia, South America, Australia, New Zealand, and South Africa. The study included a 12-week placebo-controlled, double-blind period (Period 1), and a 5-year (248-week) double-blind extension (Period 2).

Period 1: Week 1 to Week 12
Participant flow — Period 1: Week 1 to Week 12
MilestonePlacebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgUpadacitinib 15 mgUpadacitinib 30 mg
Started110111221219
Received study drug110111221219
Completed104104213201
Not completed67818
Withdrew: Adverse event3339
Withdrew: Withdrawal by subject1255
Withdrew: Lost to follow-up0102
Withdrew: Other2102
Period 2: Week 12 to Week 260
Participant flow — Period 2: Week 12 to Week 260
MilestonePlacebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgUpadacitinib 15 mgUpadacitinib 30 mg
Started103103212200
Received study drug103102207199
Switched to upadacitinib 15 mg after protocol amendment 60530126
Completed6149130120
Not completed42548280
Withdrew: Adverse event13161730
Withdrew: Withdrawal by subject14213130
Withdrew: Lost to follow-up55104
Withdrew: Coronavirus disease - 2019 (covid-19) infection1001
Withdrew: Covid-19 logistic restrictions1010
Withdrew: Other8122315

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1235.7 (29.4 to 42.1)63.8 (57.5 to 70.1)66.2 (59.9 to 72.5)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 28.1 · 95% CI 19.1 to 37.0Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 30.5 · 95% CI 21.6 to 39.4Response Rate Difference = Upadacitinib - Placebo
PrimaryPercentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12

The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 12. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 1217.2 (12.2 to 22.2)48.4 (41.8 to 55.0)47.9 (41.3 to 54.6)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 31.2 · 95% CI 23.0 to 39.5Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 30.8 · 95% CI 22.5 to 39.0Response Rate Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in in Disease Activity Score 28 (CRP) at Week 12

The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12
units on a scalePlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12-1.02 (-1.22 to -0.82)-2.20 (-2.40 to -2.00)-2.34 (-2.54 to -2.14)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Least squares (ls) mean difference: -1.18 · 95% CI -1.42 to -0.94Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -1.32 · 95% CI -1.56 to -1.08Treatment Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
units on a scalePlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12-0.25 (-0.34 to -0.17)-0.59 (-0.67 to -0.51)-0.54 (-0.62 to -0.46)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -0.33 · 95% CI -0.43 to -0.24Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -0.28 · 95% CI -0.38 to -0.18Treatment Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Short-Form 36 (SF-36) Physical Component Summary (PCS) Score at Week 12

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary (PCS) Score at Week 12
units on a scalePlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary (PCS) Score at Week 123.03 (1.88 to 4.18)7.58 (6.43 to 8.74)8.01 (6.84 to 9.18)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeat Measurement · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: 4.55 · 95% CI 3.13 to 5.98Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeat Measurement · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: 4.98 · 95% CI 3.54 to 6.42Treatment Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12

Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6. DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 1210.0 (6.0 to 13.9)30.8 (24.7 to 36.9)28.3 (22.3 to 34.3)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 20.8 · 95% CI 13.6 to 28.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 18.4 · 95% CI 11.2 to 25.5Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12

Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10. CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 1219.0 (13.8 to 24.2)40.3 (33.8 to 46.7)42.0 (35.5 to 48.5)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 21.3 · 95% CI 13.0 to 29.5Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Response rate difference: 23.0 · 95% CI 14.7 to 31.3Response Rate Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Duration of Morning Stiffness at Week 12

Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · minutes
Change From Baseline in Duration of Morning Stiffness at Week 12
minutesPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Duration of Morning Stiffness at Week 12-34.27 (-54.63 to -13.91)-85.28 (-105.61 to -64.95)-85.13 (-105.65 to -64.62)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeat Measurement · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -51.01 · 95% CI -78.14 to -23.87Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeat Measurement · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: -50.86 · 95% CI -78.19 to -23.53Treatment Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12

The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a five point Likert scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from Baseline indicates improvement.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12
units on a scalePlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 122.96 (1.62 to 4.30)7.91 (6.56 to 9.27)7.74 (6.38 to 9.11)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeat Measurement · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: 4.95 · 95% CI 3.31 to 6.60Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeat Measurement · p = <0.001 (The adjusted p-value under multiplicity control is reported, with significance achieved if the adjusted p-value is less than 0.05.) · Ls mean difference: 4.78 · 95% CI 3.12 to 6.44Treatment Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 1214.9 (10.2 to 19.6)38.0 (31.6 to 44.4)43.4 (36.8 to 49.9)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (Unadjusted p-value) · Response rate difference: 23.1 · 95% CI 15.1 to 31.0Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (Unadjusted p-value) · Response rate difference: 28.4 · 95% CI 20.4 to 36.5Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 125.9 (2.8 to 9.0)20.8 (15.5 to 26.2)26.5 (20.6 to 32.3)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (Unadjusted p-value) · Response rate difference: 14.9 · 95% CI 8.7 to 21.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (Unadjusted p-value) · Response rate difference: 20.6 · 95% CI 14.0 to 27.2Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity; * Patient global assessment of disease activity; * Patient assessment of pain; * Health Assessment Questionnaire - Disability Index (HAQ-DI); * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 1
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 18.6 (4.9 to 12.3)22.2 (16.7 to 27.6)28.3 (22.3 to 34.3)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 (Unadjusted p-value) · Response rate difference: 13.6 · 95% CI 7.0 to 20.2Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 (Unadjusted p-value) · Response rate difference: 19.7 · 95% CI 12.7 to 26.7Response Rate Difference = Upadacitinib - Placebo

Adverse events

Collected over Period 1: From first dose of study drug (placebo or upadacitinib) up to Week 12 or up to 30 days after last dose for participants who discontinued study drug prior to Week 12. Period 1+2: From first dose of upadacitinib up to 30 days after last dose (maximum of 264 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Placebo1/221 (0.5%)5/221 (2.3%)68/221 (30.8%)
Period 1: Upadacitinib 15 mg0/221 (0%)10/221 (4.5%)83/221 (37.6%)
Period 1: Upadacitinib 30 mg0/219 (0%)7/219 (3.2%)74/219 (33.8%)
Period 1+2: Upadacitinib 15 mg4/324 (1.2%)91/324 (28.1%)241/324 (74.4%)
Period1+2: Upadacitinib 30 mg7/321 (2.2%)102/321 (31.8%)233/321 (72.6%)
Period 2: Upadacitinib 15 mg After Switch2/179 (1.1%)19/179 (10.6%)51/179 (28.5%)
Most frequent serious events
Showing 10 of 244
Most frequent serious events
EventPeriod 1: PlaceboPeriod 1: Upadacitinib 15 mgPeriod 1: Upadacitinib 30 mgPeriod 1+2: Upadacitinib 15 mgPeriod1+2: Upadacitinib 30 mgPeriod 2: Upadacitinib 15 mg After Switch
PneumoniaInfections and infestations1/2210/2210/2196/32411/3210/179
OsteoarthritisMusculoskeletal and connective tissue disorders0/2211/2211/2196/3248/3212/179
COVID-19 pneumoniaInfections and infestations0/2210/2210/2196/3242/3214/179
Acute myocardial infarctionCardiac disorders0/2210/2210/2191/3245/3210/179
CholelithiasisHepatobiliary disorders0/2210/2210/2191/3244/3210/179
SepsisInfections and infestations0/2210/2210/2191/3244/3210/179
Atrial fibrillationCardiac disorders1/2210/2210/2194/3241/3210/179
PyrexiaGeneral disorders0/2210/2210/2191/3243/3210/179
Wound infection staphylococcalInfections and infestations0/2210/2211/2190/3243/3210/179
FallInjury, poisoning and procedural complications0/2210/2210/2193/3240/3210/179
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPeriod 1: PlaceboPeriod 1: Upadacitinib 15 mgPeriod 1: Upadacitinib 30 mgPeriod 1+2: Upadacitinib 15 mgPeriod1+2: Upadacitinib 30 mgPeriod 2: Upadacitinib 15 mg After Switch
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations9/22112/22112/21964/32457/3214/179
NASOPHARYNGITISInfections and infestations9/22112/22113/21960/32445/3213/179
URINARY TRACT INFECTIONInfections and infestations8/2218/2216/21955/32446/3214/179
HERPES ZOSTERInfections and infestations1/2211/2211/21927/32444/3214/179
BRONCHITISInfections and infestations5/2214/2215/21935/32442/3212/179
HYPERTENSIONVascular disorders4/2213/2212/21941/32427/3214/179
ALANINE AMINOTRANSFERASE INCREASEDInvestigations5/2211/2215/21936/32433/3212/179
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations0/2215/2217/21936/32432/3211/179
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders10/2214/2214/21936/32430/3218/179
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations6/2212/2213/21933/32425/3213/179

Baseline characteristics

The Full Analysis Set (FAS) includes all randomized participants who received at least one dose of study drug. The two placebo groups are combined for analysis of results in Period 1.

Age, Continuous
Age, Continuous(years)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean56.0 ± 12.2255.3 ± 11.4755.8 ± 11.2955.7 ± 11.65
Age, Customized
Age, Customized(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
< 40 years21232266
40 to 64 years145153145443
≥ 65 years554552152
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Female166182172520
Male553947141
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Hispanic or Latino27233080
Not Hispanic or Latino194198189581
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
White187188186561
Black or African American1013831
American Indian / Alaskan Native1012
Asian19192159
Multiple4138
Geographical Region
Geographical Region(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
North America908889267
South/Central America8101129
Western Europe24222369
Eastern Europe747673223
Asia16171548
Other98825
Prior Biological DMARD Use
Prior Biological DMARD Use(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Yes29272884
No192194191577
Duration of Rheumatoid Arthritis (RA) Diagnosis
Duration of Rheumatoid Arthritis (RA) Diagnosis(years)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean7.2 ± 7.457.3 ± 7.897.3 ± 7.867.3 ± 7.72

9 further baseline measures are reported on the registry.

08

Study locations

167 sites
  • AZ Arthritis and Rheum Assoc /ID# 148651
    Mesa, Arizona 85202, United States
  • SunValley Arthritis Center, Lt /ID# 140452
    Peoria, Arizona 85381, United States
  • AZ Arthritis and Rheum Researc /ID# 138500
    Phoenix, Arizona 85032-9306, United States
  • AZ Arthritis and Rheum Researc /ID# 139286
    Phoenix, Arizona 85032-9306, United States
  • AZ Arthritis & Rheuma Research /ID# 138598
    Phoenix, Arizona 85032, United States
  • Arizona Research Center, Inc. /ID# 140448
    Phoenix, Arizona 85053-4061, United States
  • University of Arizona Cancer Center - North Campus /ID# 140451
    Tucson, Arizona 85719-1478, United States
  • Covina Arthritis Clinic /ID# 139881
    Covina, California 91722, United States
  • T. Joseph Raoof, MD, Inc. /ID# 140964
    Encino, California 91436, United States
  • Allergy and Rheum Med Clin /ID# 146082
    La Jolla, California 92037, United States
  • Pacific Arthritis Ctr Med Grp /ID# 138744
    Los Angeles, California 90045, United States
  • Robin K. Dore MD, Inc /ID# 138688
    Tustin, California 92780, United States
  • Inland Rheum Clin Trials Inc. /ID# 138853
    Upland, California 91786, United States
  • Denver Arthritis Clinic /ID# 139876
    Denver, Colorado 80230, United States
  • Clinical Res of West FL, Inc. /ID# 138854
    Clearwater, Florida 33765, United States
  • Ctr Arthritis & Rheumatic Dise /ID# 141696
    Miami, Florida 33173, United States
  • Medallion Clinical Research Institute, LLC /ID# 140074
    Naples, Florida 34102, United States
  • Suncoast Clinical Research /ID# 138633
    New Port Richey, Florida 34652, United States
  • Omega Research Consultants /ID# 139877
    Orlando, Florida 32810, United States
  • Arthritis Center, Inc. /ID# 141363
    Palm Harbor, Florida 34684, United States
  • Institute of Arthritis Res /ID# 138548
    Idaho Falls, Idaho 83404, United States
  • OrthoIllinois /ID# 139695
    Rockford, Illinois 61114-4937, United States
  • Clinical Investigation Special /ID# 139696
    Skokie, Illinois 60076, United States
  • Springfield Clinic /ID# 138602
    Springfield, Illinois 62702-3749, United States
  • Deerbrook Medical Associates /ID# 139694
    Vernon Hills, Illinois 60061, United States
  • Indiana Univ School of Med /ID# 140077
    Indianapolis, Indiana 46202, United States
  • Bluegrass Community Research /ID# 138295
    Lexington, Kentucky 40515, United States
  • Four Rivers Clinical Research /ID# 141134
    Paducah, Kentucky 42003, United States
  • MMP Women's Health /ID# 141542
    Portland, Maine 04102, United States
  • The Center for Rheumatology & /ID# 139203
    Wheaton, Maryland 20902, United States
  • Mansfield Health Center /ID# 141357
    Mansfield, Massachusetts 02048, United States
  • Advanced Rheumatology, PC /ID# 140071
    Lansing, Michigan 48910, United States
  • Justus J. Fiechtner, MD, PC /ID# 138697
    Lansing, Michigan 48910, United States
  • Physician Res. Collaboration /ID# 138533
    Lincoln, Nebraska 68516, United States
  • Westroads Clinical Research /ID# 138304
    Omaha, Nebraska 68114, United States
  • The Center for Rheumatology /ID# 138746
    Albany, New York 12206, United States
  • PMG Research of Salisbury /ID# 141023
    Salisbury, North Carolina 28144, United States
  • PMG Research of Wilmington LLC /ID# 140951
    Wilmington, North Carolina 28401, United States
  • Cincinnati Rheumatic Disease Study Group, Inc. /ID# 138868
    Cincinnati, Ohio 45242-4468, United States
  • Arthritis Assoc of NW Ohio /ID# 140953
    Toledo, Ohio 43606, United States
  • Health Research Oklahoma /ID# 138535
    Oklahoma City, Oklahoma 73103-2400, United States
  • Altoona Ctr Clinical Res /ID# 138741
    Duncansville, Pennsylvania 16635, United States
  • Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 138689
    Summerville, South Carolina 29486-7887, United States
  • Comprehensive Arthritis Care, a division of Comprehensive Rheumatology Care PLLC /ID# 141021
    Hendersonville, Tennessee 37075-6213, United States
  • Tekton Research, Inc. /ID# 141428
    Austin, Texas 78745, United States
  • Trinity Universal Res Assoc /ID# 149271
    Carrollton, Texas 75007, United States
  • Arth and Osteo Clin Brazo Valley /ID# 147809
    College Station, Texas 77845, United States
  • Metroplex Clinical Research /ID# 138698
    Dallas, Texas 75231, United States
  • Baylor College of Medicine /ID# 138682
    Houston, Texas 77030-3411, United States
  • Houston Institute for Clin Res /ID# 138716
    Houston, Texas 77074, United States
  • Arthritis Consultants, P.A. /ID# 141138
    Killeen, Texas 76549, United States
  • Trinity Universal Research Association /ID# 148649
    Plano, Texas 75024-5283, United States
  • Accurate Clinical Management /ID# 139338
    San Antonio, Texas 78229, United States
  • Arthritis & Osteoporosis Clinic /ID# 138703
    Waco, Texas 76710, United States
  • Western Washington Arthritis C /ID# 138728
    Bothell, Washington 98021, United States
  • Arthritis Northwest, PLLC /ID# 138539
    Spokane, Washington 99204, United States
  • Aurora Rheumatology and Immunotherapy Center /ID# 139306
    Franklin, Wisconsin 53132, United States
  • Mautalen Salud e Investigacion /ID# 141419
    Buenos Aires, 1128, Argentina
  • Inst. Rheumatologic Strusberg /ID# 145648
    Cordoba, 5000, Argentina
  • Coffs Clinical Trials /ID# 138747
    Coffs Harbour, New South Wales 2450, Australia
  • Optimus Clinical Research Pty. /ID# 138769
    Kogarah, New South Wales 2217, Australia
  • Emeritus Research /ID# 138773
    Camberwell, Victoria 3124, Australia
  • Barwon Rheumatology /ID# 138772
    Geelong, Victoria 3220, Australia
  • Rheuma Zentrum Favoriten GmbH /ID# 138787
    Vienna, 1100, Austria
  • Wilhelminenspital der Stadt Wien /ID# 138788
    Wien, 1160, Austria
  • Rhumaconsult SPRL /ID# 138813
    Charleroi, Hainaut 6000, Belgium
  • UZ Gent /ID# 138806
    Gent, Oost-Vlaanderen 9000, Belgium
  • AZ Sint Lucas /ID# 141338
    Brugge, 8310, Belgium
  • University Clinical Centre of the Republic of Srpska /ID# 138819
    Banja Luka, Republika Srpska 78000, Bosnia and Herzegovina
  • University Clinical Centre of the Republic of Srpska /ID# 140372
    Banja Luka, Republika Srpska 78000, Bosnia and Herzegovina
  • Diag Consult Ctr 17 Sofia EOOD /ID# 141006
    Sofia, 1505, Bulgaria
  • Diagnostic Consultative Center /ID# 138882
    Sofia, 1612, Bulgaria
  • Manitoba Clinic /ID# 139086
    Winnipeg, Manitoba R3A IM3, Canada
  • Eastern Health /ID# 140431
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • Groupe de Recherche en Maladies Osseuses /ID# 138906
    Sainte-foy, Quebec G1V 3M7, Canada
  • Dr. Latha Naik /ID# 139089
    Saskatoon, Saskatchewan S7K 3H3, Canada
  • Klinicki bolnicki centar Rijeka /ID# 138649
    Rijeka, Primorsko-goranska Zupanija 51000, Croatia
  • Klinicka bolnica Sveti Duh /ID# 152812
    Zagreb, 10000, Croatia
  • Medical Center Kuna-Peric /ID# 140365
    Zagreb, 10000, Croatia
  • Poliklinika Bonifarm /ID# 141415
    Zagreb, 10000, Croatia
  • L.K.N. Arthrocentrum, s.r.o /ID# 141340
    Hlučín, Moravskoslezsky Kraj 748 01, Czechia
  • Revmatologie, s.r.o. /ID# 138899
    Brno, 638 00, Czechia
  • Artroscan s.r.o. /ID# 138833
    Ostrava, 722 00, Czechia
  • Nemocnice Slany /ID# 141112
    Slany, 274 01, Czechia
  • PV-MEDICAL s.r.o. /ID# 138913
    Zlin, 760 01, Czechia
  • Center of Clinical and Basic Research /ID# 141116
    Tallinn, Harjumaa 10128, Estonia
  • Paernu Hospital /ID# 138961
    Pärnu, 80010, Estonia
  • East Tallinn Central Hospital /ID# 140618
    Tallinn, 10138, Estonia
  • Helsinki Univ Central Hospital /ID# 140381
    Helsinki, 00290, Finland
  • Kiljava Medical Research /ID# 139260
    Hyvinkaa, 05800, Finland
  • South Karelia Central Hospital /ID# 139973
    Lappeenranta, 53130, Finland
  • Hopital Saint Joseph /ID# 149188
    Marseille CEDEX 08, Bouches-du-Rhone 13285, France
  • CHRU Tours - Hopital Trousseau /ID# 138969
    Chambray Les Tours, 37170, France
  • Uniklinik Koln /ID# 139084
    Köln, Nordrhein-Westfalen 50937, Germany
  • Charité Universitätsmedizin Campus Mitte /ID# 139052
    Berlin, 10117, Germany
  • Immanuel-Krankenhaus /ID# 139059
    Berlin, 13125, Germany
  • Asklepios Klinik Altona /ID# 140466
    Hamburg, 22763, Germany
  • Welcker, Planegg, DE /ID# 140467
    Planegg, 82152, Germany
  • University General Hospital of Heraklion "PA.G.N.I" /ID# 139115
    Heraklion, 71110, Greece
  • Prince of Wales Hospital /ID# 139314
    Sha Tin, Hong Kong

Showing the first 100 of 167 sites across 38 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18. PubMed 29908669 ↗
  • Bergman M, Buch MH, Tanaka Y, Citera G, Bahlas S, Wong E, Song Y, Zueger P, Ali M, Strand V. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials. Rheumatol Ther. 2022 Dec;9(6):1517-1529. doi: 10.1007/s40744-022-00483-4. Epub 2022 Sep 20. PubMed 36125701 ↗
  • Bergman M, Tundia N, Yang M, Orvis E, Clewell J, Bensimon A. Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis. Adv Ther. 2021 Dec;38(12):5649-5661. doi: 10.1007/s12325-021-01930-4. Epub 2021 Oct 12. PubMed 34636000 ↗
  • Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27. PubMed 34041702 ↗
  • Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, Burmester GR. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021 Mar;80(3):304-311. doi: 10.1136/annrheumdis-2020-218510. Epub 2020 Oct 28. Erratum In: Ann Rheum Dis. 2021 May;80(5):e83. doi: 10.1136/annrheumdis-2020-218510corr1. PubMed 33115760 ↗
  • Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther. 2019 Dec 9;21(1):272. doi: 10.1186/s13075-019-2037-1. Erratum In: Arthritis Res Ther. 2020 Jun 9;22(1):137. doi: 10.1186/s13075-020-02238-4. PubMed 31815649 ↗
  • Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis. Clin Pharmacol Ther. 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671. Epub 2019 Nov 30. PubMed 31610021 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Apr 2017, 16 months.

Results were first posted in Oct 2019, 2 years 5 months after primary completion. A results delay was requested in Jan 2018.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 16 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2015
First posted
Feb 5, 2016
StartActual
Dec 17, 2015
Primary completionActual
Apr 21, 2017
CompletionActual
Mar 10, 2022
Results delay requested
Jan 9, 2018
Results first posted
Oct 7, 2019
Last update
Apr 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02675426
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 5, 2016
Start date
Dec 17, 2015
Primary completion
Apr 21, 2017
Completion
Mar 10, 2022
Results posted
Oct 7, 2019
Last update
Apr 11, 2023

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion